These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
9. Mutant Enrichment with 3'-Modified Oligonucleotides (MEMO)-Quantitative PCR for Detection of NPM1 Mutations in Acute Myeloid Leukemia. Shin SY; Ki CS; Kim HJ; Kim JW; Kim SH; Lee ST J Clin Lab Anal; 2015 Sep; 29(5):361-5. PubMed ID: 25384962 [TBL] [Abstract][Full Text] [Related]
10. Comparison of RNA- and DNA-based methods for measurable residual disease analysis in NPM1-mutated acute myeloid leukemia. Pettersson L; Johansson Alm S; Almstedt A; Chen Y; Orrsjö G; Shah-Barkhordar G; Zhou L; Kotarsky H; Vidovic K; Asp J; Lazarevic V; Saal LH; Fogelstrand L; Ehinger M Int J Lab Hematol; 2021 Aug; 43(4):664-674. PubMed ID: 34053184 [TBL] [Abstract][Full Text] [Related]
11. [Evaluation of methods for detection of NPM1 gene mutations in acute myeloid leukemia]. Li ZP; Zhang X; Zhao XM; Li QG; Chen YM; Lu QY Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2011 Aug; 19(4):999-1004. PubMed ID: 21867632 [TBL] [Abstract][Full Text] [Related]
12. Rapid and sensitive typing of NPM1 mutations using LNA-mediated PCR clamping. Thiede C; Creutzig E; Illmer T; Schaich M; Heise V; Ehninger G; Landt O Leukemia; 2006 Oct; 20(10):1897-9. PubMed ID: 17041639 [No Abstract] [Full Text] [Related]
14. NPM1 mutation is a stable marker for minimal residual disease monitoring in acute myeloid leukaemia patients with increased sensitivity compared to WT1 expression. Kristensen T; Møller MB; Friis L; Bergmann OJ; Preiss B Eur J Haematol; 2011 Nov; 87(5):400-8. PubMed ID: 21707751 [TBL] [Abstract][Full Text] [Related]
15. Mutation of the NPM1 gene contributes to the development of donor cell-derived acute myeloid leukemia after unrelated cord blood transplantation for acute lymphoblastic leukemia. Rodríguez-Macías G; Martínez-Laperche C; Gayoso J; Noriega V; Serrano D; Balsalobre P; Muñoz-Martínez C; Díez-Martín JL; Buño I Hum Pathol; 2013 Aug; 44(8):1696-9. PubMed ID: 23465275 [TBL] [Abstract][Full Text] [Related]
16. Longitudinal minimal residual disease (MRD) evaluation in acute myeloid leukaemia with NPM1 mutation: from definition of molecular relapse to MRD-driven salvage approach. Guolo F; Minetto P; Clavio M; Miglino M; Colombo N; Cagnetta A; Cea M; Marcolin R; Todiere A; Ballerini F; Gobbi M; Lemoli RM Br J Haematol; 2019 Sep; 186(6):e223-e225. PubMed ID: 31348524 [No Abstract] [Full Text] [Related]
17. Quantitative detection of circulating nucleophosmin mutations DNA in the plasma of patients with acute myeloid leukemia. Quan J; Gao YJ; Yang ZL; Chen H; Xian JR; Zhang SS; Zou Q; Zhang L Int J Med Sci; 2015; 12(1):17-22. PubMed ID: 25552914 [TBL] [Abstract][Full Text] [Related]
18. Minimal residual disease monitoring based on FLT3 internal tandem duplication in adult acute myeloid leukemia. Abdelhamid E; Preudhomme C; Helevaut N; Nibourel O; Gardin C; Rousselot P; Castaigne S; Gruson B; Berthon C; Soua Z; Renneville A Leuk Res; 2012 Mar; 36(3):316-23. PubMed ID: 22129478 [TBL] [Abstract][Full Text] [Related]
19. Two novel NPM1 mutations in an acute myeloid leukemia patient transformed from primary myelofibrosis. Park SH; Chi HS; Shim H; Jang S; Park CJ Int J Lab Hematol; 2013 Feb; 35(1):e1-3. PubMed ID: 22978565 [No Abstract] [Full Text] [Related]